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In cystic fibrosis, ion-transport abnormalities cause problems in many organs. A small 
molecule that forms cell-membrane pores which allow ion transport, shows promise in 
studies of human cells and an animal model of the disease. See Letter p.405 
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In cystic fibrosis, abnormalities in the ion-channel protein CFTR causes problems in transport 
of the ions chloride (Cl
−
) and bicarbonate (HCO3
−
) in lung epithelial cells, which results in a 
thick build-up of airway mucus. This hinders the normal process that removes mucus, and the 
inhaled bacteria trapped within it, from the airways, and this blockage leads to persistent 
infection and inflammation, which destroys lung tissue
1
. Writing in Nature, Muraglia et al.
2
 
demonstrate that a small molecule called amphotericin B, which can form an ion channel in 
the cellular membrane of lung cells, effectively restores ion transport and antibacterial 
defences when tested using human cells from people who have cystic fibrosis and an animal 
model of the disease. 
 
 
Much progress is currently being made in efforts to develop new clinical treatments 
for cystic fibrosis. Cocktails of three drugs are now in clinical trials that might potentially 
greatly slow the progression of the disease
3,4
. Problems in CFTR reaching its usual location 
on the cell membrane is a common defect in cystic fibrosis, and two of the drugs help CFTR 
 
1 
to reach the cell membrane while the third one boosts ion transport through the channel. 
However, approximately 1,800 faulty versions of the CFTR-encoding gene associated 
with disease have been identified so far, and this diversity of mutations might mean that 
CFTR-targeting drugs will not work for everyone who has the disease
1
. 
 
Therefore interest has grown in trying to find widely applicable treatment options for cystic 
fibrosis. For example, efforts are being made to try to find ways to restore ion transport that 
bypass faulty or missing CFTR proteins by using other pathways to transport negatively 
charged ions (anions) out of the cell. For example, using anion channels that are found 
naturally in lung epithelial cells
5
 or exploiting synthetic molecules that bind anions 
selectively and function either as artificial anion channels
6
 or transporters that shuttle anions 
across a lipid membrane
7
. 
 
HCO3
−
 has crucial roles in lung-defence mechanisms and abnormalities in the 
secretion of HCO3
−
 from lung cells into the airways underlie many of the symptoms of 
cystic fibrosis. Studies of a pig model of cystic fibrosis have indicated that the absence of 
normal HCO3
−
 transport into the airways from lung cells prevents bacterial killing by 
antimicrobial factors and affects the pH and viscosity of the airway surface liquid that covers 
lung cells
8
. This liquid surrounds cellular protrusions called cilia (Fig. 1a) that beat to 
transport away the overlying mucus
8
. HCO3
−
 is essential too for the untangling of mucins 
during mucus formation
9
. In cystic fibrosis, the volume of airway surface liquid is lower 
than normal and is more acidic than normal (Fig. 1b) due to the defects in anion secretion
1,8
. 
 
 
Cellular transport proteins cause the anions Cl
−
 and HCO3
−
 to accumulate in lung 
epithelial cells, and in people who have cystic fibrosis, these anions remain trapped within the 
 
2 
cells. As a result, the high concentration of Cl
−
 and HCO3
−
 inside cells and their low 
concentration in the airway surface liquid generates a steep concentration gradient for these 
anions across the upper (apical) surface of lung cells that might suffice to drive anion exit 
without requiring an energy source for transport. Muraglia et al.
2
 therefore reasoned that a 
small-molecule HCO3
−
 transporter could exploit this concentration gradient to restore 
HCO3
−
 transport and thereby also restore the defence processes that depend on HCO3
−
 in the 
lungs of people who have cystic fibrosis. But which small molecule to use? 
 
 
Muraglia and colleagues focused on an anti-fungal agent called amphotericin B that is 
made naturally by bacteria. This small molecule might seem a peculiar choice at first sight. It 
forms non-selective ion channels that are permeable to both anions and positive ions 
(cations) and it can be toxic to human cells
10
. However, three lines of evidence made a 
persuasive case for this choice. First, its ion-channel function can be separated from its anti-
fungal activity by judicious control of the amphotericin B concentration
10
; which suggests 
that the toxicity can be managed. Second, amphotericin B restored the transport of potassium 
ions in yeast cells lacking a potassium transporter protein, demonstrating that it can provide a 
functional replacement for natural transport proteins
11
. Third, Muraglia et al. demonstrated 
that amphotericin B transported HCO3
−
 across artificial lipid membranes. 
 
Muraglia and colleagues added amphotericin B to the apical membrane of human lung 
cells that are a standard in vitro model system for studying cystic fibrosis, and this treatment 
resulted in HCO3
−
 secretion from the cells, caused the pH of the airway surface liquid to rise and 
restored the volume of airway surface liquid to a normal value (Fig. 1c), compared to the effect in 
cells that did not receive amphotericin B. The authors also tested lung epithelial cells grown in 
vitro from tissue donated by people who represented a range of CFTR variants. The 
 
3 
addition of amphotericin B to the apical surface of these cells resulted in an increase in the 
pH, a decrease in the viscosity of the airway surface liquid and an enhancement of bacterial 
killing power compared to the effect in the cells that did not receive amphotericin B. Finally, 
Muraglia et al. demonstrated in an in vivo pig model of cystic fibrosis, that if animals 
received the drug AmBisome, which contains amphotericin B and is already in use in the 
clinic, this increased the pH of the airway surface liquid, compared to the pH of this liquid in 
animals who did not receive the drug treatment. 
 
 
This study by Muraglia et al. and other work
12
 offer a proof-of-concept that small 
molecules can function as surrogates for defective or deficient transport proteins in human 
disease. Although a small molecule cannot replicate all the functions of a complex protein, 
the success of this approach will surely encourage wider exploration of such uses of small 
molecules. Why did amphotericin B work so well? The authors report that if a protein called 
the Na
+
, K
+
-ATPase, an ion transport pump located on the tissue-facing (basolateral) 
membrane of lung epithelial cells was inhibited in human lung epithelial cells grown in vitro 
from people who have cystic fibrosis, this prevented the beneficial effects of amphotericin B 
treatment. Na
+
, K
+
-ATPase activity affects cellular anion transport and the movement of ions 
it regulates affects ion transport through other transport proteins, including the import of Cl
−
 
and HCO3
−
. The data suggesting that the action of amphotericin B in the apical membrane 
required the activity of ion-transport proteins located in the basolateral membrane, is an 
example of what is called transcellular cross-talk between epithelial membranes
13
, in which 
ion entry and exit through the different surfaces of the cell is regulated to prevent cellular 
damage. 
 
 
 
 
 
 
 
4 
Muraglia and colleagues’ work raise many intriguing questions that will no doubt 
stimulate future research. For example, how much amphotericin B would be needed to fully 
restore host defences? Could it be used in combination with drugs that rescue faulty CFTR 
proteins? And would it be safe to use amphotericin B routinely throughout an individual’s 
life? As new therapeutic approaches are developed for people who have cystic fibrosis, this 
might lead to improvements not only for the treatment of all people with this disease but 
perhaps also for other lung conditions, which have disease characteristics that are similar to 
those of cystic fibrosis. 
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Figure 1 | The small molecule amphotericin B can tackle lung problems that occur in 
cystic fibrosis. a, Lung epithelial cells are bathed in a layer of airway surface liquid on which 
mucus floats. Cellular protrusions called cilia beat to propel (arrows) this mucus and trapped 
bacteria from the airways. Mucus removal, the killing of trapped bacteria and the maintenance 
of a normal volume of airway surface fluid at physiological pH requires the presence of 
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HCO3
−
 and Cl
−
 due to activity of a network of cellular proteins that transport ions. In certain 
lung epithelial cells, these include the protein CFTR in the fluid-facing (apical) membrane, 
which transports HCO3
−
 and Cl
−
 out of the cell, and the Na
+
, K
+
-ATPase protein in the 
tissue-facing (basolateral) membrane of the cell. b, In cystic fibrosis, CFTR is absent from the 
apical membrane of epithelial cells, which causes a build-up of HCO3
−
 and Cl
−
 within these 
cells (due to the action of a network of ion transport proteins (not shown) that also depend on 
the presence of functional Na
+
, K
+
-ATPase). The absence of secretion of HCO3
−
 and Cl
−
 
results in the formation of airway surface fluid that is more acidic than normal (red), of a 
smaller volume than normal, and thicker mucus than usual and abnormalities in mucus 
removal and in the killing of bacterial cells within the mucus. c, Muraglia et al.
2
 demonstrate 
in studies of human cells and in a pig model of cystic fibrosis that if the small molecule ion 
channel amphotericin B (AmB) is used to treat cells that lack CFTR on their apical surface, 
amphotericin B restores the missing ion transport and can prevent the problems that arise 
when CFTR is absent from the apical surface of lung cells. 
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